Abelacimab reduce el sangrado comparado con rivaroxaban independientemente de la edad, con el potencial de una mayor reducción en el riesgo en los mayores de 75a #abelacimab #AF #bleeding jamanetwork.com/journals/jam...
The factor XI inhibitor #abelacimab may be a safer alternative to #DOACs for patients with atrial fibrillation #AFib, as the treatment led to a significant reduction in major and clinically relevant non-major #bleeding events compared with #rivaroxaban: ow.ly/xcpz50VM9eY
#HemeSky #Heme/Onc
ノバルティス、循環器領域向けにAnthos Therapeutics社を買収へ #ノバルティス #Abelacimab #Anthos_Therapeutics
ノバルティスは、循環器領域の強化を目指し、Anthos Therapeutics社を約9.25億ドルで買収することを発表しました。この動きは、心房細動患者向け新薬開発の加速を意味します。
Using #mono-antibody #abelacimab to treat atrial fibrillation can prevent #blood clots and reduce the risk of #bleeding.
"New Treatment of #Atrialfibrillation"
Using #mono-antibody #abelacimab to treat atrial fibrillation can prevent #blood clots and reduce the risk of #bleeding.
AZALEA-TIMI 71 nej.md/3PJcknN
23) The authors concluded that #abelacimab tended to provide a greater absolute risk reduction for 🩸 in pts on #antiplatelet therapy than a conventional #DOAC, even beyond the difference seen in #AZALEA for pts treated overall. The #FXI hypothesis continues to be strengthened!
20b) The interesting finding is that the addition of #OAP therapy to #anticoagulation created another differential between #rivaroxaban & #abelacimab: adding #OAP to riva significantly ⬆️ 🩸, but adding OAP to abelacimab did not!
13) The 🩸reduction with investigational #abelacimab compared with on-label #rivaroxaban was indeed impressive:
11) Need an #AZALEA refresher? You can still earn credit by reviewing our live #tweeetorial from #AHA23 at cardiometabolic-ce.com/antithrombot.... AZALEA was a Ph 2 comparison of #abelacimab vs #rivaroxaban in pts w/#AF + mod/high risk of #stroke.
10) So @SidPatelMD was in the room here at #AHA24 for @cardiomet_CE as @TIMIStudyGroup #fellow Samer Al Said @sameralsaid presented a second preplanned analysis from #AZALEA TIMI_71, looking at concomitant use of #OAPs with either #abelacimab or #rivaroxaban.
8b) New approaches for #stroke ⬇️ in #AFib have been #MAb against #FXI and small molecule inhibitors of #FXIa. Leading candidate from each of these categories currently in Ph 3 trials: MAb #abelacimab in #LILAC #TIMI-76 & small molecule #milvexian in #LIBREXIA_AF.
